Drugs / Tamoxifen
Tamoxifen
also known as
tamoxifen citrate · TAM · Nolvadex (tamoxifen) · TMX · TY-302 · ApoTamox · Baby Tamoxifen · BabyTAM · +36 more
Small molecule targets ESR1
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | SOLTAMOX | — | 2018-09-25 | fda.gov ↗ |
| Label expansions (9) | US (FDA) | NOLVADEX | — | 1986-12-03 – 2009-03-13 | fda.gov ↗ |
| Approved | US (FDA) | NOLVADEX | — | 1977-12-30 | fda.gov ↗ |
Trials 223 · started per year
today
US approved 1977
1
1
1
1
2
5
3
2
2
2
3
2
7
8
6
7
3
5
5
6
12
5
6
6
3
4
8
12
8
16
7
8
7
10
6
7
5
11
7
19771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
Also used as a comparator or background therapy in 192 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02913430 Comparator | Apr 2018 → Apr 2022 | breast cancer | Shannon Puhalla | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT06218303 Background | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05755581 Comparator | Apr 2023 → Apr 2025 | breast cancer | Sohag University | Unknown | No outcome recorded |
| Phase 1 | NCT04504331 Background | Oct 2020 → Oct 2021 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | Jennifer Lee Caswell-Jin | Terminated | No outcome recorded |
| Phase 1 | NCT02936206 Comparator | Oct 2016 → May 2020 | breast cancer | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 1 | NCT02586675 Background | Feb 2016 → May 2017 | female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01971515 Background | Dec 2013 → Aug 2018 | cancer | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT01393990 Background | Sep 2008 → Feb 2013 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00005822 Background | Apr 2000 → Dec 2002 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00009997 Background | Mar 1999 → Jan 2004 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT00003080 Background | Sep 1996 → May 2001 | ovarian cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07708194 Background | Jun 2025 → Feb 2027 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02285179 Background | Nov 2014 → May 2022 | breast cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 270 trials | ||||||
| Phase 2 | NCT07610733 Background | Jun 2026 → Sep 2027 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07287098 Comparator | May 2026 → Jan 2029 expected | breast neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07581834 Background | Jan 2026 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07071038 Comparator | Oct 2025 → Aug 2026 overdue | breast cancer | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07101159 Background | Sep 2025 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348134 Background | Mar 2025 → Jul 2034 expected | HER2 positive breast carcinoma, Her2-receptor negative breast cancer, female breast carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT06369285 Background | Nov 2024 → Jun 2027 expected | hormone receptor-positive breast cancer | Puma Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05941520 Comparator | Oct 2024 → Aug 2027 expected | ductal breast carcinoma in situ, lobular breast carcinoma in situ | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06179303 Background | Jul 2024 → Mar 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06033092 Comparator | Jun 2024 → Dec 2025 overdue | ATM-related cancer predisposition, CDH1-related diffuse gastric and lobular breast cancer syndrome, CHEK2-related cancer predisposition, PALB2-related cancer predisposition +4 | European Institute of Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06075953 Comparator | Feb 2024 → Nov 2028 expected | ductal breast carcinoma in situ | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT06001762 Background | Oct 2023 → Jan 2025 overdue | breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05983107 Background | Jul 2023 → Jul 2026 overdue | hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05659563 Comparator | Jul 2023 → Jan 2025 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT05982093 Comparator | Feb 2023 → Dec 2026 expected | hormone receptor-positive breast cancer | SOLTI Breast Cancer Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05306041 Background | Jan 2023 → Oct 2026 expected | HER2 positive breast carcinoma | GBG Forschungs GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT05463601 Background | Aug 2022 → Jan 2025 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05472792 Comparator | May 2022 → Apr 2027 expected | breast cancer | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04985266 Comparator | Mar 2022 → Sep 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT05035836 Background | Nov 2021 → Dec 2028 expected | HER2 positive breast carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04389580 Comparator | Sep → Oct 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04300790 Background | Oct 2020 → Jun 2022 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT04460430 Background | Jul 2020 → Nov 2021 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 2 | NCT03879577 Background | Nov 2019 → Mar 2023 overdue | HER2 positive breast carcinoma, female breast carcinoma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04059484 Comparator | Oct 2019 → Feb 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT04023292 Comparator | Jul 2019 → Jul 2023 | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03573648 Comparator | Nov 2018 → Sep 2026 expected | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03058939 Background | Nov 2018 → Apr 2019 | female breast carcinoma | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT03715413 Background | Aug → Dec 2018 | breast fibroadenoma | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT03184090 Background | Jun 2017 → Oct 2020 | metastatic malignant neoplasm | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03078751 Background | Jun 2017 → Mar 2020 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02993159 Comparator | May 2017 → Mar 2021 | ductal breast carcinoma in situ, estrogen-receptor positive breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT03024580 Comparator | Mar 2017 → Mar 2020 | breast neoplasm | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02970682 Background | Oct 2016 → Jan 2019 | breast neoplasm | Evgen Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02630693 Comparator | Apr 2016 → Aug 2018 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT02384239 Background | Oct 2015 → Jan 2021 | hormone receptor-positive breast cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02592083 Background | Oct 2015 → Feb 2019 overdue | hormone receptor-positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02206984 Comparator | Sep 2015 → Jul 2024 | breast cancer | Priscilla McAuliffe | Completed | No outcome recorded |
| Phase 2 | NCT02584465 Comparator | Aug 2015 → Sep 2021 | ovarian carcinoma | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 2 | NCT02228681 Comparator | May 2015 → Jan 2018 | endometrial cancer | GOG Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02366130 Background | Feb 2015 → Dec 2020 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02291913 Background | Dec 2014 → Jan 2019 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02404844 Background | Dec 2014 → Sep 2017 | breast cancer | University Hospital, Essen | Completed | No outcome recorded |
| Phase 2 | NCT02269670 Background | Nov 2014 → Jan 2021 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT02040857 Background | Jan 2014 → May 2018 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01685255 Comparator | Aug 2012 → Oct 2014 | ovarian carcinoma | Incyte Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00952731 Comparator | Dec 2009 → Sep 2011 | ductal breast carcinoma in situ, estrogen-receptor positive breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00728949 Comparator | Aug 2008 → Mar 2012 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00398489 Background | Oct 2006 → ? | breast cancer | Technical University of Munich | Unknown | No outcome recorded |
| Phase 2 | NCT00183963 Comparator | Aug 2006 → Jun 2008 | breast carcinoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00240071 Background | Oct 2005 → Mar 2009 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00119262 Background | Oct 2005 → Aug 2009 | male breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00077168 Background | Apr 2004 → Sep 2017 | breast carcinoma | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| Phase 2 | NCT00206544 Comparator | Jan 2004 → Dec 2007 | manic bipolar affective disorder, schizoaffective disorder | The Alfred | Completed | No outcome recorded |
| Phase 2 | NCT00080743 Comparator | Jan 2004 → Apr 2005 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00229697 Background | Oct 2003 → Dec 2006 | breast neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00210028 Background | Aug 2003 → Aug 2008 | breast neoplasm | Institut Claudius Regaud | Terminated | No outcome recorded |
| Phase 2 | NCT00290654 Background | Dec 2002 → Mar 2013 | breast cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00637871 Comparator | Nov 2002 → Jun 2005 | gynecomastia disorder, prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00031720 Background | Mar 2002 → Apr 2006 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00005908 Background | Jun 2000 → Jan 2008 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003992 Background | Aug 1999 → Jan 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003953 Background | Feb 1999 → Nov 2001 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003199 Background | Nov 1997 → Dec 2009 | estrogen-receptor negative breast cancer, estrogen-receptor positive breast cancer, inflammatory breast carcinoma, male breast carcinoma +2 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003042 Background | May 1997 → Feb 2010 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00003050 Background | Apr 1997 → Mar 2000 | breast cancer | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00003035 Background | Mar 1997 → Jun 2001 | breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00287534 Comparator | Nov 1996 → Sep 2004 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00003099 Comparator | May 1996 → Jun 2000 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002679 Background | Feb 1994 → Jan 2002 | breast cancer | Yale University | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02101788 Comparator | Apr 2014 → Apr 2019 | borderline ovarian serous tumor, micropapillary serous carcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00684216 Comparator | Apr 2008 → May 2012 | breast cancer | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 390 trials | ||||||
| Phase 3 | NCT07349069 Comparator | Mar 2026 → Dec 2030 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06585969 Comparator | Jan 2026 | basal-like breast carcinoma, estrogen-receptor positive breast cancer, luminal B breast carcinoma | Danish Breast Cancer Cooperative Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT07213206 Comparator | Oct 2025 → Sep 2032 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07019363 Comparator | Jun 2025 → May 2029 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07190443 Comparator | Feb 2025 → Feb 2034 expected | breast cancer | Japanese Foundation for Cancer Research | Recruiting | No outcome recorded |
| Phase 3 | NCT06404775 Comparator | Jan 2025 → Jan 2029 expected | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06449027 Background | Aug 2024 → Nov 2025 overdue | breast carcinoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06440967 Background | Jul 2024 → Jun 2026 overdue | — | Astellas Pharma Global Development, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05512364 Comparator | Dec 2023 → Nov 2032 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT05952557 Comparator | Oct 2023 → Mar 2030 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05894239 Background | Sep 2023 → Dec 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 Background | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 Background | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05774951 Comparator | Mar 2023 → Apr 2027 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05780567 Background | Mar 2023 → Dec 2026 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05645536 Background | Dec 2022 → Jun 2028 expected | breast cancer | Tolmar Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05514054 Comparator | Oct 2022 → Oct 2027 expected | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05306340 Comparator | Aug 2022 → Jul 2025 overdue | estrogen-receptor positive breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05128773 Comparator | Feb → Oct 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT04961996 Comparator | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04906395 Background | Jul 2021 → Apr 2026 overdue | female breast carcinoma | Tolmar Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04852887 Comparator | Jun 2021 → Apr 2031 expected | female breast carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT04134598 Comparator | Feb 2021 → Mar 2030 expected | breast cancer | Careggi University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04584853 Background | Dec 2020 → Oct 2030 expected | female breast carcinoma | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04024462 Background | Feb 2020 → Dec 2021 | HER2 positive breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03820830 Background | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03969121 Comparator | Jul 2019 → Dec 2021 | female breast carcinoma, hormone receptor-positive breast cancer | Kyoto Breast Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT03137368 Comparator | Aug 2018 → Oct 2023 | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03493854 Background | Jun 2018 → Jul 2019 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03081234 Background | Mar 2018 → Nov 2025 | breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT03423199 Background | Feb 2018 → Sep 2025 | breast cancer | National Cancer Center, Japan | Unknown | No outcome recorded |
| Phase 3 | NCT03351062 Comparator | Nov 2017 → Dec 2025 | female breast carcinoma | Chinese Anti-Cancer Association | Unknown | No outcome recorded |
| Phase 3 | NCT02914158 Comparator | Mar 2016 → Dec 2023 | breast cancer | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02278120 Background | Nov 2014 → Aug 2017 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02062489 Comparator | May 2014 → May 2025 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01674140 Background | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01638247 Comparator | Aug 2012 → May 2018 | male breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01564056 Background | Apr 2012 → Apr 2022 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT01758146 Comparator | Jan 2012 → Jan 2020 | breast cancer | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT02995772 Comparator | Nov 2011 → Nov 2018 | breast cancer | Dharmais National Cancer Center Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01272037 Background | Feb 2011 → Feb 2023 overdue | ductal breast carcinoma in situ, invasive breast carcinoma, synchronous bilateral breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00629278 Background | Dec 2007 → Dec 2010 | breast cancer | University Hospital of Modena | Unknown | No outcome recorded |
| Phase 3 | NCT00605267 Comparator | Oct 2007 → Nov 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00541086 Comparator | Mar 2007 → Jul 2020 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00433589 Comparator | Feb 2007 → Mar 2020 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00310180 Background | Apr 2006 → Mar 2018 overdue | breast adenocarcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00293540 Comparator | Feb 2006 → Feb 2014 | breast cancer | International Breast Cancer Research Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00412022 Comparator | Mar 2004 → Nov 2024 | breast cancer | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 3 | NCT00201851 Background | Jan 2004 → Dec 2011 | breast cancer | International Breast Cancer Research Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00066703 Comparator | Nov 2003 → Mar 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00072462 Comparator | Sep 2003 → Dec 2015 | breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 3 | NCT00411203 Comparator | Apr 2003 → Jun 2006 | bipolar disorder | Stanley Medical Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00053898 Comparator | Jan 2003 → Mar 2015 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00053911 Background | Nov 2002 → Apr 2004 | breast cancer | UNICANCER | Terminated | No outcome recorded |
| Phase 3 | NCT01579734 Comparator | Mar 2002 → Dec 2018 | breast cancer | European Institute of Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT00279448 Comparator | Jan 2002 → Nov 2008 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00047099 Background | Aug 2001 → Feb 2012 | breast cancer | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT00016276 Background | May 2001 → Mar 2005 | female breast carcinoma, inflammatory breast carcinoma, poisoning | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00005970 Background | May 2000 → Apr 2005 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00004125 Background | Nov 1999 → May 2007 | breast cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00295646 Comparator | Jun 1999 → Mar 2008 | breast cancer | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00003906 Comparator | May 1999 → Dec 2005 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00241449 Comparator | Nov 1998 → Mar 2007 | breast cancer, metastatic neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00003679 Background | Nov 1998 → ? | breast cancer | Scottish Cancer Therapy Network | Unknown | No outcome recorded |
| Phase 3 | NCT00003680 Background | Nov 1998 → ? | breast cancer | Scottish Cancer Therapy Network | Unknown | No outcome recorded |
| Phase 3 | NCT00003972 Background | Jul 1998 → Mar 2003 | breast cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00784940 Comparator | Jun 1998 → Mar 2005 | bone disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00784862 Comparator | Jun 1998 → Mar 1999 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00784680 Comparator | Apr 1998 → Apr 2004 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00286117 Comparator | Mar 1998 → May 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00038467 Comparator | Feb 1998 → Jun 2003 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00814125 Comparator | Jun 1997 → Dec 2005 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00002967 Background | May 1997 → Mar 2006 | female breast carcinoma | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00003032 Background | Apr 1997 → Apr 2001 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00002920 Background | Mar 1997 → Dec 2006 | breast cancer, endometrial cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00003013 Background | Oct 1996 → Mar 2009 | female breast carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Completed | No outcome recorded |
| Phase 3 | NCT00002864 Comparator | Sep 1996 → Dec 2007 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00590785 Background | Aug 1996 → Jun 1997 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00002772 Background | Jul 1996 → Feb 2004 | breast cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT00849030 Comparator | Jul 1996 → Jun 2001 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00152178 Background | Jul 1996 → Apr 2008 | breast cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00002784 Background | Jun 1996 → Aug 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00002707 Background | Dec 1995 → Jun 2002 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00002720 Background | Dec 1995 → Dec 2012 | breast cancer | European Institute of Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00002755 Background | Nov 1995 → Jun 1999 | breast cancer | Scottish Cancer Therapy Network | Completed | No outcome recorded |
| Phase 3 | NCT00002646 Background | Oct 1995 → Feb 2004 | breast cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002582 Background | Jun 1993 → Apr 2007 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00002528 Background | May 1993 → Dec 2002 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00309491 Background | Dec 1990 → Jan 1996 | female breast carcinoma | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00793377 Background | ? → Sep 2001 | female breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05161195 Background | Jul 2022 → Jun 2030 expected | metastatic malignant neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04933240 Comparator | May 2022 → Jun 2024 | — | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02344940 Comparator | Dec 2014 → Aug 2018 | breast cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02467686 Comparator | Jan 2014 → Sep 2017 | — | Irmandade da Santa Casa de Misericordia de Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01612871 Background | Jun 2012 → Jan 2016 | female breast carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT00537771 Comparator | Sep 2007 → Dec 2011 | breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07447024 Background | Mar → Jun 2026 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07145827 Background | Jan 2024 → Jul 2025 | breast cancer, endometrial disorder | Uruk University | Completed | No outcome recorded |
| — | NCT05890287 Background | May 2023 → May 2026 overdue | hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT06120595 Background | Nov 2022 → Nov 2023 | — | Helse Stavanger HF | Unknown | No outcome recorded |
| — | NCT04292886 Comparator | Oct 2019 → Dec 2020 | uterine disorder | Nanjing University | Unknown | No outcome recorded |
| — | NCT02488603 Background | Aug 2015 → Aug 2018 | breast cancer | National Cancer Center, Korea | Unknown | No outcome recorded |
| — | NCT01897441 Background | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| — | NCT01503905 Comparator | Dec 2011 → May 2018 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01027416 Comparator | Dec 2009 → Dec 2015 | breast cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT00827307 Comparator | Jun 2008 → Jun 2011 | hyperlipidemia | Zhejiang Cancer Hospital | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2003-02-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Tamoxifen Citrate Tablets tevapharm.com ↗ |
| 2000-06-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Tamoxifen Citrate 10 mg tevapharm.com ↗ |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 419 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tamoxifen | “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗398“Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days...” NCT03969121 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total...” NCT03081234 ↗ “Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3.” NCT05826964 ↗ “Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months.” NCT03078751 ↗ “The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane.” NCT04961996 ↗ “Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)” NCT06585969 ↗ “1-month GnRH (goserelin 3.6 mg depot or goserelin 3.6 mg implant or leuprolide 3.75 mg depot) +endocrine therapy (aromatase inhibitor/tamoxifen±CDK4/6 inhibition)” NCT07610733 ↗ “aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)” NCT00240071 ↗ “Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .” NCT00847366 ↗ “If side effects persist after the 1st line switch, the participant will have the option to switch to another AI not yet tried, or to tamoxifen at 20mg daily” NCT07071038 ↗ “For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants” NCT04024462 ↗ “Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.” NCT06449027 ↗ “Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.” NCT05333328 ↗ “Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men” NCT05306041 ↗ “The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).” NCT06120595 ↗ “Premenopausal patients: Tamoxifen (10 mg, orally, twice daily, for 5 years) or Toremifene (60 mg, orally, once daily, for 5 years)” NCT07153757 ↗ “standard endocrine therapy( aromatase inhibitors or tamoxifen，Ovarian function suppression agents may be added if premenopausal)” NCT07213206 ↗ “(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).” NCT01564056 ↗ “["Letrozole","Anastrozole","Exemestane","Tamoxifen","Leuprolide, or other LHRH agonist (per investigator discretion)"]” NCT04569747 ↗ “either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily” NCT01897441 ↗ “A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study.” NCT02366130 ↗ “Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.” NCT05983107 ↗ “The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.” NCT07483307 ↗ “Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab” NCT01950182 ↗ “All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week).” NCT04915846 ↗ “Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen” NCT02448420 ↗ “premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane” NCT04383275 ↗ “Selective estrogen receptor modulator (SERM) - Tamoxifen 20 mg by mouth daily (pre-menopausal)” NCT06218303 ↗ “Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd” NCT02040857 ↗ “Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients” NCT05755581 ↗ “either NCT or NET with goserelin and tamoxifen, followed by goserelin and anastrozole.” PMID 40331570 ↗ May 2025 “Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)” NCT03573648 ↗ “tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy” NCT03493854 ↗ “Tamoxifen: 10-20 mg, orally, twice daily (continuous), every 28 days” NCT05861830 ↗ “5. Tamoxifen 20mg oral administration every day (1 cycle = 4 weeks)” NCT06837792 ↗ “Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen” NCT05890287 ↗ “or tamoxifen (20 mg per day orally; if premenopausal)” PMID 28238593 ↗ Feb 2017 “Neratinib plus Fulvestrant, Exemestane or Tamoxifen” NCT04460430 ↗ “tamoxifen, Letrozole, Anastrazole, Exemestane, etc.” NCT04023292 ↗ “Patients with RS ≤ 15 are treated with tamoxifen.” NCT07671885 ↗ “20 mg of tamoxifen tablet by mouth once daily or” NCT06369285 ↗ “continue tamoxifen treatment (TAM group)” PMID 30643455 ↗ Dec 2018 “Tamoxifen 20mg and anastrozole 1 mg” NCT01016665 ↗ “Sunitinib, Tamoxifen, Temsirolimus” NCT02788201 ↗ “Tamoxifen 20 mg: once daily.” NCT07447024 ↗ “tamoxifen oral daily tablet” NCT03820830 ↗ “Allowed ETs are tamoxifen” NCT05894239 ↗ “Drug: Tamoxifen” NCT00309478 ↗ “Tamoxifen” NCT03948568 ↗ |
| Known as | ApoTamox | “All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week).” NCT04915846 ↗ |
| Known as | Baby Tamoxifen | “Randomized Double Blind Phase II Trial of Baby Exemestane vs Baby Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.” NCT06364267 ↗ |
| Known as | BabyTAM | “The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.” NCT06364267 ↗ |
| Known as | Emblon | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Fentamox 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Fentamox 20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | I.C.I.46474 CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | ICI 46,474 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | ICI-47699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Kentadex | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Kessar | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Kessar 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Kessar 20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Mammaton | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Noltam | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | NOLVADEX | “NOLVADEX (tamoxifen)” NCT00232661 ↗ |
| Known as | Nolvadex (tamoxifen) | “Nolvadex (tamoxifen)” NCT01897441 ↗1“Nolvadex (tamoxifen)” NCT00240071 ↗ |
| Known as | Nolvadex d | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Nolvadex fte | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Nourytam | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Novaldex | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | NSC-180973 | “Arm I: Antiestrogen Therapy. Tamoxifen, TMX, NSC-180973.” NCT00929591 ↗ |
| Known as | NSC-727681 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | NSC-757345 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Oestrifen-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Oestrifen-20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Oestrifen-40 | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Soltamox | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Soltamox (tamoxifen) | “Soltamox (tamoxifen)” NCT01897441 ↗ |
| Known as | TAM | “The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer” PMID 31518174 ↗ Sep 20194“Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)” NCT02890082 ↗ “Tamoxifen (TAM), a synthetic nonsteroidal antiestrogen, has been widely used in the treatment of breast cancer.” NCT00026585 ↗ “All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily during 48 weeks.” NCT03354039 ↗ “In both arms, tamoxifen (TAM) was concurrently administered for 2 years.” PMID 19638976 ↗ Jul 2009 |
| Known as | Tamofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Tamofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Tamoplex | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Tamoxifen (Nolvadex) | “Tamoxifen (Nolvadex)” NCT00866554 ↗ |
| Known as | tamoxifen citrate | “Premenopausal patients receive tamoxifen citrate and post- or perimenopausal patients receive either tamoxifen citrate or an aromatase inhibitor (AI), or both of these drugs in...” NCT00499083 ↗31“Random assignment to oral tamoxifen citrate, 20 mg/d, and gel placebo or 4-hydroxytamoxifen gel, 2 mg/d per breast, and oral placebo, for 4 to 10 weeks, followed by DCIS resection.” PMID 37870954 ↗ Dec 2023 “To evaluate the change in endoxifen levels after an increase in tamoxifen citrate dose from 20 mg to 40 mg” NCT00764322 ↗ “oral tamoxifen citrate twice daily on days 1-42” NCT00492687 ↗ “tamoxifen citrate (Tamoxifen)” NCT00365599 ↗ “Tamoxifen Citrate 20Mg Tab” NCT00002644 ↗ “Tamoxifen Citrate 20Mg Tab” NCT07289035 ↗ “Drug: tamoxifen citrate” NCT00068419 ↗ “Drug: tamoxifen citrate” NCT00002920 ↗ “Drug: Tamoxifen Citrate” NCT00118157 ↗ “Drug: tamoxifen citrate” NCT00053898 ↗ “Drug: Tamoxifen citrate” NCT00108069 ↗ “Drug: tamoxifen citrate” NCT00003992 ↗ “Drug: tamoxifen citrate” NCT00003857 ↗ “Drug: tamoxifen citrate” NCT00002528 ↗ “Drug: tamoxifen citrate” NCT00003042 ↗ “tamoxifen citrate” NCT00002542 ↗ |
| Known as | Tamoxifene | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Tamoxifeni citras | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Tamoxifeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | TMX | “Patients receive oral tamoxifen (TMX) daily continously for 5 years.” NCT00002967 ↗1“Arm I: Antiestrogen Therapy. Tamoxifen, TMX, NSC-180973.” NCT00929591 ↗ |
| Known as | Tomaxasta | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | TY-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04433494 ↗ |
| Known as | Zemide | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Zitazonium | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Known as | Zynoplex | ChEMBL registry synonym — accepted as the source's own label CHEMBL83 ↗ |
| Action | Inhibit | “the anti-estrogen, tamoxifen, significantly reduced circulating IGF I levels” NCT00001436 ↗ |
| Modality | Small molecule | “Tamoxifen (TAM), a synthetic nonsteroidal antiestrogen, has been widely used in the treatment of breast cancer.” NCT00026585 ↗ |
| Route | Oral | “Patients then receive oral tamoxifen for 5 years.” NCT00002528 ↗ |
| Target | ESR1 | “Estrogen receptor alpha modulator” CHEMBL83 ↗ |